Successful treatment of young infants presenting neonatal diabetes mellitus with continuous subcutaneous insulin infusion before genetic diagnosis
- 600 Downloads
Neonatal diabetes mellitus (NDM) is defined as hyperglycemia and impaired insulin secretion with onset within 6 months of birth. While rare, NDM presents complex challenges regarding the management of glycemic control. The availability of continuous subcutaneous insulin infusion pumps (CSII) in combination with continuous glucose monitoring systems (CGM) provides an opportunity to monitor glucose levels more closely and deliver insulin more safely.
We report four cases of young infants with NDM successfully treated with CSII and CGM. Moreover, in two cases with Kir 6.2 mutation, we describe the use of CSII in switching therapy from insulin to sulfonylurea treatment.
Insulin pump requirement for the 4 neonatal diabetes cases was the same regardless of disease pathogenesis and c-peptide levels. No dilution of insulin was needed. The use of an integrated CGM system helped in a more precise control of BG levels with the possibility of several modifications of insulin basal rates. Moreover, as showed in the first two case-reports, when the treatment was switched from insulin to glibenclamide, according to identification of Kir 6.2 mutation and diagnosis of NPDM, the CSII therapy demonstrated to be helpful in allowing gradual insulin suspension and progressive introduction of sulfonylurea.
During the neonatal period, the use of CSII therapy is safe, more physiological, accurate and easier for the insulin administration management. Furthermore, CSII therapy is safe during the switch of therapy from insulin to glibenclamide for infants with permanent neonatal diabetes mellitus.
KeywordsNeonatal diabetes mellitus Hyperglycemia Continuous subcutaneous insulin infusion pumps (CSII) Continuous glucose monitoring systems (CGMS)
We would like to thank the Diabetes Study Group of Italian Society of Pediatric Endocrinology and Diabetology (ISPED) for the continuous collaboration and discussion on Neonatal Diabetes.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Human and animal rights
This article does not contain any studies with human or animal subjects performed by the any of the authors.
Informed consent was obtained from all individual participants included in the study.
- 22.Ortolani F, Piccinno E, Grasso V et al (2015) Diabetes associated with dominant insulin gene mutations: outcome of 24-month, sensor-augmented insulin pump treatment. Acta Diabetol [Epub ahead of print]Google Scholar
- 28.Ross PL, Milburn J, Reith DM, et al (2015) Clinical review: insulin-pump associated adverse events in adults and children. Acta Diabetol [Epub ahead of print]Google Scholar
- 29.Eli Lilly and Company Limited (2014) Humalog 100 U/ml, solution for injection in vial, Humalog 100 U/ml, solution for injection in Cartridge, Humalog KwikPen 100 U/ml, solution for injection: summary of product characteristics. Basingstoke, UKGoogle Scholar